Therapeutic Asset Ratings

831 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sargramostim Gastric Adenocarcinoma	Mayo Clinic	P1/2	B (57)
Cobimetinib Cutaneous Melanoma	Mayo Clinic	P2	B (56)
Psma-Hbed-Cc Hepatocellular Carcinoma	Mayo Clinic	P2	B (56)
TRASTUZUMAB Prostate Cancer	Mayo Clinic	P2	B (56)
FLUTICASONE Cervical Cancer	Mayo Clinic	P2	CCC (55)
FLUTICASONE Endometrial Cancer	Mayo Clinic	P2	CCC (55)
Ibrutinib Metastatic Melanoma	Mayo Clinic	P2	CCC (55)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Prostate Cancer	Mayo Clinic	P2	CCC (55)
Sargramostim Cervical Cancer	Mayo Clinic	P2	CCC (55)
Sargramostim Endometrial Carcinoma	Mayo Clinic	P2	CCC (55)
Clinisol 15% Obesity Disorder	Mayo Clinic	P4	CCC (54)
DEXTROSE Obesity Disorder	Mayo Clinic	P4	CCC (54)
Dabrafenib Metastatic Malignant Neoplasm In The Brain	Mayo Clinic	P2	CCC (54)
Dasatinib Cognitive Disorder	Mayo Clinic	P2	CCC (54)
FDOPA Glioblastoma	Mayo Clinic	P2	CCC (54)
Hyaluronidase zzxf Castration-Resistant Prostate Carcinoma	Mayo Clinic	P2	CCC (54)
Selinexor Non-Hodgkin Lymphoma	Mayo Clinic	P1/2	CCC (54)
Zofran Lymphoma, B-Cell	Mayo Clinic	P1/2	CCC (54)
Doxycycline Obesity Disorder	Mayo Clinic	P4	CCC (53)
17-beta-estradiol Advanced Triple-Negative Breast Carcinoma	Mayo Clinic	P2	CCC (53)
17-beta-estradiol Recurrent Breast Carcinoma	Mayo Clinic	P2	CCC (53)
18F-ASIS Inflammatory Demyelinating Disease	Mayo Clinic	P2	CCC (53)
2-(1-HEXYLOXYETHYL)-2-DEVINYLPYROPHEOPHORBIDE-A Locally Advanced Pancreatic Adenocarcinoma	Mayo Clinic	P2	CCC (53)
Acellular Pertussis Vaccine Advanced Fallopian Tube Carcinoma	Mayo Clinic	P2	CCC (53)
Acellular Pertussis Vaccine Advanced Fallopian Tube High Grade Serous Adenocarcinoma	Mayo Clinic	P2	CCC (53)

Showing 276 to 300 of 831 assets

PreviousPage 12 of 34Next